Table 1.
Patient demographic and baseline disease characteristics
| Volasertib (N = 19) | |
|---|---|
| Median age, years (range) | 73 (53–86) |
| <65 years | 2 (10.5) |
| 65–75 years | 9 (47.4) |
| ≥75 years | 8 (42.1) |
| Male/female, n (%) | 7 (36.8)/12 (63.2) |
| Baseline ECOG PS, n (%) | |
| 0 | 6 (31.6) |
| 1 | 11 (57.9) |
| 2 | 2 (10.5) |
| Disease state, n (%) | |
| Refractory | 7 (36.8) |
| Relapsed | 6 (31.6) |
| Relapsed and refractory | 2 (10.5) |
| Untreated | 4 (21.1) |
| AML considered secondary, n (%)a | 7 (36.8) |
| Preceding MDS | 4 (21.1) |
| Prior therapy with topoisomerase II inhibitor | 1 (5.3) |
| Other | 2 (10.5) |
| Karyotype, n (%)a | |
| Normal | 9 (47.4) |
| Complex | 6 (31.6) |
| Neither | 4 (21.1) |
a
Percentages do not sum to total due to rounding. AML, acute myeloid leukemia; ECOG PS, Eastern Co‐operative Oncology Group Performance Score; MDS, myelodysplastic syndrome.